Publication: Acute Ischaemic Stroke In A Covid-19 Patient On Baricitinib- A Causal Effect Or A Multifactorial Relationship?
Loading...
Date
2022
Journal Title
Journal ISSN
Volume Title
Publisher
USIM Press
Abstract
Coronavirus disease 2019 (COVID-19), a multisystemic disorder caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been associated with both venous and arterial thromboses. The hypercoagulable state of the disease poses a challenge to the patient’s management. We herein report a case of acute ischaemic stroke in a COVID-19 patient who had been treated with three days of Baricitinib, an immunotherapy that can potentially augment the thrombotic risks. The case highlights the dilemma faced when initiating immunotherapy in a COVID-19 patient and emphasises the importance of evaluating the patient’s thrombotic risks, balanced against the benefit of immunotherapy, to facilitate the selection of ideal candidates for the immunotherapy.
Description
Vol. 8 (2022): Special Issue on Communicable and Non-Communicable Disease, Multidisciplinary Case Reports
Keywords
Ischaemic Stroke, COVID-19, Arterial Thrombosis, Baricitinib
Citation
Tan, W. M., Hana Maizuliana Solehan, Sarah Zulaikha Samad, M Firdaus A Bakar, Nor Safiqah Sharil, Nur Ezzaty Mohammad Kazmin, Fatimah Zanirah, & Koon Ket Sia. (2022). Acute Ischaemic Stroke in a COVID-19 Patient on Baricitinib - A Causal Effect or a Multifactorial Relationship?. Malaysian Journal of Science Health & Technology, 8, 21–24. https://doi.org/10.33102/mjosht.v8i.265